Our research seeks to understand the cellular and molecular mechanisms that govern immune tolerance in order to prevent and reverse Type 1 Diabetes and enhance the success of organ transplantation. My graduate research as an MSTP student at Penn contributed to the understanding of the role played by B lymphocytes in the development of autoimmune disease. This research formed part of the foundation for current efforts to use B cell directed therapies to prevent diabetes, studies in which Vanderbilt is participating through the Type 1 Diabetes TrialNet and for which I participate as a co-investigator. We also previously extended these studies to demonstrate that B lymphocytes are absolutely required for some forms of transplantation tolerance induction in murine models. These studies suggest the presence of regulatory B cells which have yet to be defined. A main present focus of the lab is to understand how B lymphocytes regulate immune tolerance to transplants and how this cell type participates in broken tolerance in autoimmune disease such as Type 1 diabetes.

As part of a comprehensive program to understand immune regulation, we also actively investigate the mechanism of action of other regulatory CD4 and CD8 T lymphocytes which are critical for the prevention of autoimmune disease and for the establishment of transplantation tolerance. This research has revealed several new interactions required for the development and function of these cells and has identified inflammation as a factor that counter-regulates these regulatory cells. 

My research has been funded by the National Institutes of Health, the American Diabetes Association, and the Juvenile Diabetes Research Foundation. I serve as a reviewer for the Journal of Immunology, Diabetes, the American Journal of Transplantation, and the Annals of the New York Academy of Science. Our research has been presented at the Scientific Sessions of the American Diabetes Association, the annual meeting of the Pediatric Academic Societies, and the American Transplant Congress. We have published in the Journal of Immunology, Diabetes, Transplantation International, the Journal of Autoimmunity, and Nature Medicine. Our research program has also been recognized by the Society for Pediatric Research with the 2007 House Officer Research Award and by Vanderbilt University with the David Karzon, Joe M. Strayhorn, Elliot V. Newman, and Vanderbilt Scholar in Diabetes Awards.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Physician-Scientist Training and Programming in Pediatric Residency Programs: A National Survey. Burns AM, Moore DJ, Forster CS, Powell W, Thammasitboon S, Hostetter MK, Weiss P, Boyer D, Ward MA, Blankenburg R, Heyman MB, Rassbach CE, McPhillips H, French A, Nguyen S, Byrne BJ, Parsons DW, Gonzalez F, Nowalk AJ, Ho J, Kumar S, Orange JS, Ackerman KG (2022) J Pediatr : 5-9.e3
    › Primary publication · 34280401 (PubMed)
  2. The Rapid Transition to Telemedicine and Its Effect on Access to Care for Patients With Type 1 Diabetes During the COVID-19 Pandemic. Tilden DR, Datye KA, Moore DJ, French B, Jaser SS (2021) Diabetes Care 44(6): 1447-1450
    › Primary publication · 33849938 (PubMed) · PMC8247503 (PubMed Central)
  3. The Dual Burden of Type 1 Diabetes and COVID-19. Gregory JM, Moore DJ (2021) Ann Intern Med 174(5): 703-704
    › Primary publication · 33497267 (PubMed) · PMC8279007 (PubMed Central)
  4. Perspectives from the Society for Pediatric Research: advice on sustaining science and mentoring during COVID-19. Forster CS, Nguyen ST, Powell WT, Moore DJ, Ho J, Heyman MB, Wenger TL, Gonzalez F, Hostetter M, Nowalk A, Rassbach CE, Boyer D, Weiss P, Blankenburg RL, Orange JS, Ackerman KG, Burns AM, National Pediatric Physician-Scientist Collaborative Workgroup (2021) Pediatr Res 90(4): 738-743
    › Primary publication · 33469179 (PubMed) · PMC7814517 (PubMed Central)
  5. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. Gregory JM, Slaughter JC, Duffus SH, Smith TJ, LeStourgeon LM, Jaser SS, McCoy AB, Luther JM, Giovannetti ER, Boeder S, Pettus JH, Moore DJ (2021) Diabetes Care 44(2): 526-532
    › Primary publication · 33268335 (PubMed) · PMC7818316 (PubMed Central)
  6. The Peripheral Peril: Injected Insulin Induces Insulin Insensitivity in Type 1 Diabetes. Gregory JM, Cherrington AD, Moore DJ (2020) Diabetes 69(5): 837-847
    › Primary publication · 32312900 (PubMed) · PMC7171956 (PubMed Central)
  7. Correlating maternal iodine status with neonatal thyroid function in two hospital populations in Ghana: a multicenter cross-sectional pilot study. Dei-Tutu SA, Manful A, Heimburger DC, Malechi H, Moore DJ, Oppong SA, Russell WE, Aliyu MH (2020) BMC Pediatr 20(1): 26
    › Primary publication · 31964362 (PubMed) · PMC6974977 (PubMed Central)
  8. Regulation of Diabetogenic Immunity by IL-15-Activated Regulatory CD8 T Cells in Type 1 Diabetes. Stocks BT, Wilson CS, Marshall AF, Hoopes EM, Moore DJ (2019) J Immunol 203(1): 158-166
    › Primary publication · 31127035 (PubMed) · PMC6581590 (PubMed Central)
  9. Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2). Gregory JM, Smith TJ, Slaughter JC, Mason HR, Hughey CC, Smith MS, Kandasamy B, Greeley SAW, Philipson LH, Naylor RN, Letourneau LR, Abumrad NN, Cherrington AD, Moore DJ (2019) Diabetes 68(8): 1565-1576
    › Primary publication · 31092478 (PubMed) · PMC6692813 (PubMed Central)
  10. B lymphocytes protect islet β cells in diabetes prone NOD mice treated with imatinib. Wilson CS, Spaeth JM, Karp J, Stocks BT, Hoopes EM, Stein RW, Moore DJ (2019) JCI Insight
    › Primary publication · 30964447 (PubMed) · PMC6538336 (PubMed Central)
  11. Pancreas Volume Declines During the First Year After Diagnosis of Type 1 Diabetes and Exhibits Altered Diffusion at Disease Onset. Virostko J, Williams J, Hilmes M, Bowman C, Wright JJ, Du L, Kang H, Russell WE, Powers AC, Moore DJ (2019) Diabetes Care 42(2): 248-257
    › Primary publication · 30552135 (PubMed) · PMC6341292 (PubMed Central)
  12. Cutting Edge: IL-1α and Not IL-1β Drives IL-1R1-Dependent Neonatal Murine Sepsis Lethality. Benjamin JT, Moore DJ, Bennett C, van der Meer R, Royce A, Loveland R, Wynn JL (2018) J Immunol 201(10): 2873-2878
    › Primary publication · 30305325 (PubMed) · PMC6219910 (PubMed Central)
  13. Healthy Donor Polyclonal IgMs Diminish B-Lymphocyte Autoreactivity, Enhance Regulatory T-Cell Generation, and Reverse Type 1 Diabetes in NOD Mice. Wilson CS, Chhabra P, Marshall AF, Morr CV, Stocks BT, Hoopes EM, Bonami RH, Poffenberger G, Brayman KL, Moore DJ (2018) Diabetes 67(11): 2349-2360
    › Primary publication · 30131391 (PubMed) · PMC6198348 (PubMed Central)
  14. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA in New-Onset Type 1 Diabetes. Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ, Type 1 Diabetes TrialNet ATG-GCSF Study Group (2018) Diabetes Care 41(9): 1917-1925
    › Primary publication · 30012675 (PubMed) · PMC6105329 (PubMed Central)
  15. Limited achievement of NIH research independence by pediatric K award recipients. Good M, McElroy SJ, Berger JN, Moore DJ, Wynn JL (2018) Pediatr Res 84(4): 479-480
    › Primary publication · 29904137 (PubMed) · PMC6289685 (PubMed Central)
  16. Host Expression of the CD8 Treg/NK Cell Restriction Element Qa-1 is Dispensable for Transplant Tolerance. Stocks BT, Wilson CS, Marshall AF, Brewer LA, Moore DJ (2017) Sci Rep 7(1): 11181
    › Primary publication · 28894277 (PubMed) · PMC5593978 (PubMed Central)
  17. ERAD-icating mutant insulin promotes functional insulin secretion. Moore DJ (2017) Sci Transl Med 9(373)
    › Primary publication · 28100837 (PubMed)
  18. Grave effects of a specific immune therapy. Moore DJ (2016) Sci Transl Med 8(367): 367ec192
    › Primary publication · 27903860 (PubMed)
  19. Hematopoietic Stem Cell Mobilization Is Necessary but Not Sufficient for Tolerance in Islet Transplantation. Stocks BT, Thomas AB, Elizer SK, Zhu Y, Marshall AF, Wilson CS, Moore DJ (2017) Diabetes 66(1): 127-133
    › Primary publication · 27797908 (PubMed) · PMC5204317 (PubMed Central)
  20. New onset diabetes mellitus after heart transplantation in children is a common but potentially modifiable burden. Moore DJ (2016) Pediatr Transplant 20(7): 886-887
    › Primary publication · 27726266 (PubMed)
  21. Use of the Electronic Medical Record to Assess Pancreas Size in Type 1 Diabetes. Virostko J, Hilmes M, Eitel K, Moore DJ, Powers AC (2016) PLoS One 11(7): e0158825
    › Primary publication · 27391588 (PubMed) · PMC4938534 (PubMed Central)
  22. Targeting IL-17A attenuates neonatal sepsis mortality induced by IL-18. Wynn JL, Wilson CS, Hawiger J, Scumpia PO, Marshall AF, Liu JH, Zharkikh I, Wong HR, Lahni P, Benjamin JT, Plosa EJ, Weitkamp JH, Sherwood ER, Moldawer LL, Ungaro R, Baker HV, Lopez MC, McElroy SJ, Colliou N, Mohamadzadeh M, Moore DJ (2016) Proc Natl Acad Sci U S A 113(19): E2627-35
    › Primary publication · 27114524 (PubMed) · PMC4868456 (PubMed Central)
  23. Lupus-Prone Mice Resist Immune Regulation and Transplant Tolerance Induction. Stocks BT, Wilhelm AJ, Wilson CS, Marshall AF, Putnam NE, Major AS, Moore DJ (2016) Am J Transplant 16(1): 334-41
    › Primary publication · 26372909 (PubMed) · PMC4718751 (PubMed Central)
  24. Neonatal CD71+ Erythroid Cells Do Not Modify Murine Sepsis Mortality. Wynn JL, Scumpia PO, Stocks BT, Romano-Keeler J, Alrifai MW, Liu JH, Kim AS, Alford CE, Matta P, Weitkamp JH, Moore DJ (2015) J Immunol 195(3): 1064-70
    › Primary publication · 26101326 (PubMed) · PMC4506905 (PubMed Central)
  25. A review of adolescent adherence in type 1 diabetes and the untapped potential of diabetes providers to improve outcomes. Datye KA, Moore DJ, Russell WE, Jaser SS (2015) Curr Diab Rep 15(8): 51
    › Primary publication · 26084580 (PubMed) · PMC4692366 (PubMed Central)
  26. Regulation of B lymphocyte responses to Toll-like receptor ligand binding during diabetes prevention in non-obese diabetic (NOD) mice. Wilson CS, Elizer SK, Marshall AF, Stocks BT, Moore DJ (2016) J Diabetes 8(1): 120-31
    › Primary publication · 25564999 (PubMed) · PMC4598313 (PubMed Central)
  27. Dysregulation of T lymphocyte proliferative responses in autoimmunity. Elizer SK, Marshall AF, Moore DJ (2014) PLoS One 9(8): e106347
    › Primary publication · 25171173 (PubMed) · PMC4149551 (PubMed Central)
  28. An immunosufficient murine model for the study of human islets. Zhao G, Moore DJ, Kim JI, Lee KM, O'Connor M, Yang M, Marshall AF, Lei J, Schuetz C, Markmann JF, Deng S (2014) Xenotransplantation 21(6): 567-73
    › Primary publication · 25041432 (PubMed) · PMC4262653 (PubMed Central)
  29. Early life establishment of site-specific microbial communities in the gut. Romano-Keeler J, Moore DJ, Wang C, Brucker RM, Fonnesbeck C, Slaughter JC, Li H, Curran DP, Meng S, Correa H, Lovvorn HN, Tang YW, Bordenstein S, George AL, Weitkamp JH (2014) Gut Microbes 5(2): 192-201
    › Primary publication · 24637795 (PubMed) · PMC4063844 (PubMed Central)
  30. Type 1 diabetes mellitus. Gregory JM, Moore DJ, Simmons JH (2013) Pediatr Rev 34(5): 203-15
    › Primary publication · 23637249 (PubMed)
  31. Bioluminescence imaging reveals dynamics of beta cell loss in the non-obese diabetic (NOD) mouse model. Virostko J, Radhika A, Poffenberger G, Dula AN, Moore DJ, Powers AC (2013) PLoS One 8(3): e57784
    › Primary publication · 23483929 (PubMed) · PMC3590285 (PubMed Central)
  32. Factors that influence parental attitudes toward enrollment in type 1 diabetes trials. Buscariollo DL, Davidson MA, Black M, Russell WE, Rothman RL, Moore DJ (2012) PLoS One 7(8): e44341
    › Primary publication · 22937171 (PubMed) · PMC3429434 (PubMed Central)
  33. Regulatory properties of the intestinal microbiome effecting the development and treatment of diabetes. Romano-Keeler J, Weitkamp JH, Moore DJ (2012) Curr Opin Endocrinol Diabetes Obes 19(2): 73-80
    › Primary publication · 22357099 (PubMed) · PMC3560352 (PubMed Central)
  34. Clinical assessment of HNF1A and GCK variants and identification of a novel mutation causing MODY2. Shoemaker AH, Zienkiewicz J, Moore DJ (2012) Diabetes Res Clin Pract 96(2): e36-9
    › Primary publication · 22341299 (PubMed) · PMC3560353 (PubMed Central)
  35. Inhibition of transplantation tolerance by immune senescence is reversed by endocrine modulation. Zhao G, Moore DJ, Kim JI, Lee KM, O'Connor MR, Duff PE, Yang M, Lei J, Markmann JF, Deng S (2011) Sci Transl Med 3(87): 87ra52
    › Primary publication · 21677198 (PubMed) · PMC3767303 (PubMed Central)
  36. Can technological solutions for diabetes replace islet cell function? Gregory JM, Moore DJ (2011) Organogenesis 7(1): 32-41
    › Primary publication · 21289480 (PubMed) · PMC3082032 (PubMed Central)
  37. In vivo islet protection by a nuclear import inhibitor in a mouse model of type 1 diabetes. Moore DJ, Zienkiewicz J, Kendall PL, Liu D, Liu X, Veach RA, Collins RD, Hawiger J (2010) PLoS One 5(10): e13235
    › Primary publication · 20949090 (PubMed) · PMC2950856 (PubMed Central)
  38. An unexpected counter-regulatory role of IL-10 in B-lymphocyte-mediated transplantation tolerance. Zhao G, Moore DJ, Lee KM, Kim JI, Duff PE, O'Connor MR, Hirohashi T, Lei J, Yang M, Markmann JF, Deng S (2010) Am J Transplant 10(4): 796-801
    › Primary publication · 20199511 (PubMed) · PMC2934759 (PubMed Central)
  39. Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation. Huang X, Moore DJ, Ketchum RJ, Nunemaker CS, Kovatchev B, McCall AL, Brayman KL (2008) Endocr Rev 29(5): 603-30
    › Primary publication · 18664617 (PubMed) · PMC2819735 (PubMed Central)
  40. A direct comparison of rejection by CD8 and CD4 T cells in a transgenic model of allotransplantation. Porrett PM, Lee MK, Lian MM, Wang J, Caton AJ, Deng S, Markmann JF, Moore DJ (2008) Arch Immunol Ther Exp (Warsz) 56(3): 193-200
    › Primary publication · 18512028 (PubMed) · PMC2766493 (PubMed Central)
  41. Inhibition of ICAM-1/LFA-1 interactions prevents B-cell-dependent anti-CD45RB-induced transplantation tolerance. Huang X, Moore DJ, Mohiuddin M, Lian MM, Kim JI, Sonawane S, Wang J, Gu Y, Yeh H, Markmann JF, Deng S (2008) Transplantation 85(5): 675-80
    › Primary publication · 18337659 (PubMed) · PMC2934773 (PubMed Central)
  42. Cutting edge: transplant tolerance induced by anti-CD45RB requires B lymphocytes. Deng S, Moore DJ, Huang X, Lian MM, Mohiuddin M, Velededeoglu E, Lee MK, Sonawane S, Kim J, Wang J, Chen H, Corfe SA, Paige C, Shlomchik M, Caton A, Markmann JF (2007) J Immunol 178(10): 6028-32
    › Primary publication · 17475825 (PubMed)
  43. NOD B-cells are insufficient to incite T-cell-mediated anti-islet autoimmunity. Moore DJ, Noorchashm H, Lin TH, Greeley SA, Naji A (2005) Diabetes 54(7): 2019-25
    › Primary publication · 15983202 (PubMed)
  44. Resistance to anti-CD45RB-induced tolerance in NOD mice: mechanisms involved. Moore DJ, Huang X, Lee MK, Lian MM, Chiaccio M, Chen H, Koeberlein B, Zhong R, Markmann JF, Deng S (2004) Transpl Int 17(5): 261-9
    › Primary publication · 15138669 (PubMed)
  45. Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Greeley SA, Katsumata M, Yu L, Eisenbarth GS, Moore DJ, Goodarzi H, Barker CF, Naji A, Noorchashm H (2002) Nat Med 8(4): 399-402
    › Primary publication · 11927947 (PubMed)